The role of enoxaparin in interventional management of patients with acute coronary syndromes.
Interventional management strategies involving early angiography and percutaneous coronary intervention (PCI) are increasingly widespread in the management of patients with acute coronary syndromes (ACS). Notwithstanding the benefits of early intervention, there is a significant risk of postprocedural thrombotic complications and a need to optimize antithrombotic regimens for use before and during PCI. It is clear that the current standard therapy with unfractionated heparin (UFH) and aspirin can be improved upon, in terms of both efficacy and safety. The low-molecular-weight heparin(s) (LMWHs) offer pharmacologic and practical advantages over UFH. The LMWH enoxaparin has recently emerged as the anticoagulant of choice for the acute management of ACS. Enoxaparin has also demonstrated sustained benefits over UFH in patients proceeding to PCI, and as a procedural anticoagulant. Combination therapy with enoxaparin and a glycoprotein IIb/IIIa inhibitor may further improve the efficacy and safety of antithrombotic treatment during coronary interventions, as a result of the drugs' complementary mechanisms of action. Early clinical evidence supports the use of enoxaparin in combination with glycoprotein IIb/IIIa inhibitors in high-risk patients with ACS. Ongoing, large-scale, randomized controlled studies will help to clarify the role of enoxaparin in interventional cardiology, either as the primary anticoagulant or as part of a combination regimen, and to define optimal regimens for treatment.
Grines
Cindy L
CL
William Beaumont Hospital, Division of Cardiology, Cardiology Administration/3rd Floor Heart Center, 3601 W. Thirteen Mile Road, Royal Oak, Michigan 48073-6769, USA. Cgrines@smtpgw.beaumont.edu
O'Neill
William
W
D000208:Acute Disease; D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use*; D001779:Blood Coagulation Factors / Q000187:drug effects; D006328:Cardiac Catheterization / Q000187:drug effects; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017984:Enoxaparin / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D013577:Syndrome
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D017984:Enoxaparin